Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study

NCT02545842 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02545842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02545842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
September 7, 2015
Completion date
April 20, 2018
Enrollment
947 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus